4 research outputs found
ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΊΠΈΡΡΠΎΠ·Π½ΠΎΠΉ ΡΠ½Π΄ΠΎΠΊΡΠΈΠ½Π½ΠΎΠΉ ΠΎΠΏΡΡ ΠΎΠ»ΠΈ ΠΏΠΎΠ΄ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π»ΡΡΠ΅Π²ΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² (ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅)
Nonfunctioning neuroendocrine tumors (NFET) account for up to 33% of the neuroendocrine tumors of the pancreas, ranging from 1 to20 cmin diameter and showing a higher malignancy rate, up to 90%. The clinical presentation of nonfunctioning neuroendocrine tumors is nonspecific. These tumors, in fact, are predominantly characterized by an expansive growth pattern; therefore, they are clinically silent until adjacent viscera and structures are involved. This makes it difficult to diagnose NFET at an early stage. Correct diagnosis is typically delayed by several years. About 15% of pancreatic NFET are cystic and difficult to differentiation from other cystic pancreatic lesions. In such cases, the important role played by hypervascular rim in the arterial phase image. Literature review and case report ΠΎf diagnostics and treatment of Neuroendocrine Tumor with cystic transformation are presented in the article.Β ΠΠ΅ΡΡΠ½ΠΊΡΠΈΠΎΠ½ΠΈΡΡΡΡΠΈΠ΅ Π½Π΅ΠΉΡΠΎΡΠ½Π΄ΠΎΠΊΡΠΈΠ½Π½ΡΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ (NFET) ΡΠΎΡΡΠ°Π²Π»ΡΡΡ Π΄ΠΎ 33% ΠΎΡ Π½Π΅ΠΉΡΠΎΡΠ½Π΄ΠΎΠΊΡΠΈΠ½Π½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΠΏΠΎΠ΄ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, Π΄ΠΈΠ°ΠΌΠ΅ΡΡΠΎΠΌ ΠΎΡ 1 Π΄ΠΎ20 ΡΠΌ, Ρ ΠΊΠΎΡΡΡΠΈΡΠΈΠ΅Π½ΡΠΎΠΌ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΡΡΠΈ Π΄ΠΎ 90%. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ Π½Π΅ΡΡΠ½ΠΊΡΠΈΠΎΠ½ΠΈΡΡΡΡΠ΅ΠΉ Π½Π΅ΠΉΡΠΎΡΠ½Π΄ΠΎΠΊΡΠΈΠ½Π½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π½Π΅ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½Ρ Π»ΠΈΠ±ΠΎ ΠΌΠΎΠ³ΡΡ ΠΎΡΡΡΡΡΡΠ²ΠΎΠ²Π°ΡΡ Π²ΠΎΠ²ΡΠ΅. ΠΡΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΡΡ ΡΠΊΡΠΏΠ°Π½ΡΠΈΠ²Π½ΡΠΌ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΎΠΌ ΡΠΎΡΡΠ°, ΠΏΠΎΡΡΠΎΠΌΡ ΠΎΠ½ΠΈ ΠΌΠΎΠ³ΡΡ ΡΠ΅Π±Ρ Π½ΠΈΠΊΠ°ΠΊ Π½Π΅ ΠΏΡΠΎΡΠ²Π»ΡΡΡ Π΄ΠΎ Π²ΠΎΠ²Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠΈΠ»Π΅Π³Π°ΡΡΠΈΡ
Π²Π½ΡΡΡΠ΅Π½Π½ΠΈΡ
ΠΎΡΠ³Π°Π½ΠΎΠ² ΠΈ ΡΡΡΡΠΊΡΡΡ. ΠΡΠΎ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π·Π°ΡΡΡΠ΄Π½ΡΠ΅Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΡ Π½Π° ΡΠ°Π½Π½Π΅ΠΉ ΡΡΠ°Π΄ΠΈΠΈ, Π² ΡΠ²ΡΠ·ΠΈ Ρ ΡΠ΅ΠΌ ΠΏΠΎΡΡΠ°Π½ΠΎΠ²ΠΊΠ° Π΄ΠΈΠ°Π³Π½ΠΎΠ·Π° Π·Π°ΠΏΠ°Π·Π΄ΡΠ²Π°Π΅Ρ Π½Π° Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ Π»Π΅Ρ. ΠΠΊΠΎΠ»ΠΎ 15% ΠΏΠ°Π½ΠΊΡΠ΅Π°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
NFET ΠΈΠΌΠ΅ΡΡ ΠΏΠΎΠ»ΠΎΡΡΡ, ΡΡΠΎ Π·Π°ΡΡΡΠ΄Π½ΡΠ΅Ρ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΡ Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ ΠΊΠΈΡΡΠΎΠ·Π½ΡΠΌΠΈ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡΠΌΠΈ ΠΏΠΎΠ΄ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. Π ΡΠ°ΠΊΠΈΡ
ΡΠ»ΡΡΠ°ΡΡ
ΠΏΠ°ΡΠΎΠ³Π½ΠΎΠΌΠΎΠ½ΠΈΡΠ½ΡΠΌ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠΌ ΡΠ²Π»ΡΠ΅ΡΡΡ Π½Π°Π»ΠΈΡΠΈΠ΅ Π³ΠΈΠΏΠ΅ΡΠ²Π°ΡΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ ΠΎΠ±ΠΎΠ΄ΠΊΠ° Π² Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ ΡΠ°Π·Ρ ΠΊΠΎΠ½ΡΡΠ°ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ. Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΠΎΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΈ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Π½Π΅ΠΉΡΠΎΡΠ½Π΄ΠΎΠΊΡΠΈΠ½Π½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΏΠΎΠ΄ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Ρ ΠΊΠΈΡΡΠΎΠ·Π½ΠΎΠΉ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΠ΅ΠΉ ΡΡΡΡΠΊΡΡΡΡ.
PeptoGridβRescoring Function for AutoDock Vina to Identify New Bioactive Molecules from Short Peptide Libraries
Peptides are promising drug candidates due to high specificity and standout safety. Identification of bioactive peptides de novo using molecular docking is a widely used approach. However, current scoring functions are poorly optimized for peptide ligands. In this work, we present a novel algorithm PeptoGrid that rescores poses predicted by AutoDock Vina according to frequency information of ligand atoms with particular properties appearing at different positions in the target protein’s ligand binding site. We explored the relevance of PeptoGrid ranking with a virtual screening of peptide libraries using angiotensin-converting enzyme and GABAB receptor as targets. A reasonable agreement between the computational and experimental data suggests that PeptoGrid is suitable for discovering functional leads
Data_Sheet_1_The novel peptide LCGM-10 attenuates metabotropic glutamate receptor 5 activity and demonstrates behavioral effects in animal models.docx
We employed a structural bioinformatics approach to develop novel peptides with predicted affinity to the binding site for negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGluR5). Primary screening in zebrafish (Danio rerio) revealed a stimulatory effect of two peptides, LCGM-10 and LCGM-15. Target validation studies using calcium ion flux imaging and a luciferase reporter assay confirmed mGluR5 as the target. LCGM-10 showed greater potency than LCGM-15; it was comparable to that of the mGluR5 NAM 2-methyl-6-(phenylethynyl) pyridine (MPEP). Rodent behavioral screening in the open field and elevated plus maze revealed increased locomotor activity in both tests after acute LCGM-10 treatment, supported by further analysis of home cage spontaneous locomotor activity (SLA). The stimulating effect of a single LCGM-10 administration on SLA was evident up to 60βmin after administration and was not accompanied by hypokinetic rebound observed for caffeine. According to our results, LCGM-10 has therapeutic potential to treat hypo- and dyskinesias of various etiologies. Further investigation of LCGM-10 effects in the delay discounting model of impulsive choice in rats revealed reduced trait impulsivity after single and chronic administrations, suggesting potential implication for attention deficit hyperactivity disorder, obsessive compulsive disorder, and addictions.</p